Revolution, Achieve, Disc Medicine rise after FDA unveils fast-track review list

** Shares of drug developer Revolution Medicines RVMD.O up 7.7% at $53.51 premarket

** Late on Thursday, U.S. FDA announced nine products under a new fast-track review process

** Selected drugs could get approval within one to two months of filing a complete application; typical review time is 10 to 12 months

** Products include RVMD's daraxonrasib for pancreatic cancer, Achieve Life Sciences' ACHV.O cytisinicline for nicotine dependence related to e-cigarette or vaping use and Disc Medicine's IRON.O bitopertin for porphyria

** Shares of ACHV and IRON were up between 17% and 19% in premarket trading

** Brokerage Oppenheimer says daraxonrasib's first approval could come as early as mid-2026

** Eli Lilly's LLY.N experimental weight-loss pill, orforglipron, was expected to be included in the list

** Separately, Trump signaled the price of LLY's Danish rival Novo Nordisk's weight-loss drug would be lowered

** LLY shares down 3.7% premarket

** As of last close, RVMD up 13.58%, IRON up 17.3%, LLY up 6.1% while ACHV down 12.5% YTD